Navigation Links
Diasome Pharmaceuticals, Inc. Announces Issuance of Oral Insulin Patent by the US PTO
Date:2/25/2015

Cleveland, OH (PRWEB) February 25, 2015

Diasome Pharmaceuticals, Inc. (http://www.diasome.com) has received notice from its licensor, SDG, Inc., that SDG has received a notice of allowance for its novel oral hepatic targeted insulin technology, called Oral HDV Insulin. This patent, entitled “Orally Bioavailable Lipid Constructs,” has been assigned US Patent Number 8,962,015 and covers composition of matter claims related to the use of Diasome’s proprietary oral Hepatocyte Directed Vesicles (“HDV”) as a system for enabling oral insulin administration.

“While most oral protein and peptide delivery technologies under development require relatively large quantities of the drug in order to be effective, Diasome’s Phase 2 human results demonstrate the efficacy of very low doses of insulin when delivered by the HDV system. The issuance of this new patent further validates and supports Diasome’s strong pipeline of cell specific targeting technologies for treating both forms of diabetes and obesity,” said W. Blair Geho, MD, PhD, Diasome’s Chief Scientific Officer. “This technology has been enabled for late stage human clinical testing by the US FDA, and we look forward to moving forward in our development effort for orally administered protein therapies.”

About Diasome Pharmaceuticals, Inc.

Diasome Pharmaceuticals, Inc. is focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. Based on more than thirty years of research and development in the fields of cell receptor targeting, insulin replacement, and hepatic (liver) glucose metabolism, the Company’s pipeline includes multiple injected and oral formulations of liver targeted insulins for both Type 1 and Type 2 diabetic patients that are Phase 3 ready. In addition, Diasome is developing a first-in-class oral compound for the Type 2 diabetes population that is based upon new insights into normal glucose metabolism and a novel mechanism of action, along with a nanotechnology-based oral compound that may have a significant impact in treating obesity.

Read the full story at http://www.prweb.com/releases/2015/02/prweb12535403.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering
2. Synthetic Biology Market by Tool, Technology (Bioinformatics, Nanotechnology, Gene Synthesis, Cloning & Sequencing), Application (Biofuels, Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast to 2018
3. PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website
4. Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody
5. Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC
6. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
7. Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin
8. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
9. Life Cycle Management of Biopharmaceuticals, New Life Science Webinar Hosted by Xtalks
10. Auxilium Pharmaceuticals, Inc. To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
11. Whitehouse Laboratories Announces Diamond Level Sponsorship of ISTA TransPack Forum 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2020)... (PRWEB) , ... June 22, 2020 , ... ... lead glutamine antagonist, DRP-104, will be presented June 22-24 during the American Association ... of DRP-104; and, the other profiles the potent, consistent single agent activity in ...
(Date:6/11/2020)... ... June 08, 2020 , ... Greffex, a leading ... use of proprietary clean viral vectors, recently announced a key manufacturing agreement with ... platform is the world’s most successful gene therapy delivery vehicle (vector) with broad ...
(Date:6/11/2020)... ... ... Reducing carbon emissions has been and will continue to be a major topic of ... reduce CO2 is something we can’t avoid. , To protect the environment, oil ... are created from recycled cooking oil or crops. Unfortunately, these sources are not sustainable. ...
(Date:5/30/2020)... ... 2020 , ... Medrio, Inc., the leading provider of eClinical ... Cytovale, Inc., a medical technology company dedicated to revolutionizing diagnostics for conditions like ... in (FPI) in just seven days. The Cytovale technology will allow patients with ...
Breaking Biology Technology:
(Date:6/5/2020)... MURRIETA, Calif. (PRWEB) , ... June 04, 2020 , ... ... , has filed a new patent application for simplified sample preparation for Next ... technology that will greatly reduce cost, time, and complexity of sample preparation. , “I ...
(Date:6/2/2020)... ... June 02, 2020 , ... ... and RFID labeling software developer and solutions provider, today reported that the ... labeling accuracy and compliance by 100%, resulting in greater efficiency for global ...
(Date:5/28/2020)... INDIANAPOLIS (PRWEB) , ... May 27, 2020 , ... ... of hc1 Workforce Advisor™ , a solution that uniquely combines lab testing ... to help employers systematically support the ongoing health and safety of employees returning ...
Breaking Biology News(10 mins):